Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver disease in the U.S., with an estimated 20 million people displaying evidence of fat-related liver injury. The rapid rise in NAFLD since 1970 suggests that environmental factors play a critical role in the pathogenesis of the disease. Epidemiologic studies point to dietary sugar as a specific risk factor for NAFLD;sugar can harm liver cells by being converted to toxic long- chain saturated fatty acids (SFA) through the process of de novo lipogenesis (DNL). DNL is not the only route by which SFA enter the liver, but studies from our laboratory suggest that DNL-derived SFA are particularly hepatotoxic. In contrast, SFA present in the diet induce relatively little liver injury in vivo. Interestingly, despite their apparently innocuous nature when fed with other nutrients, dietary SFA can synergize with dietary sugar to promote severe fatty liver disease. The hypothesis that forms the basis of this proposal is that DNL SFA are major mediators of hepatocellular injury in NAFLD. Accordingly, dietary nutrients or nutrient combinations that cause significant fatty liver disease likely do so in direct relationship to their ability to stimulate DNL.
Specific Aim 1 will investigate the possibility that dietary saturated fat synergizes with dietary sugar to promote fatty liver disease not by contributing directly to a cytotoxic SFA pool, but instead by amplifying DNL and increasing hepatic production of toxic DNL SFA. Experiments will also address the hypothesis that dietary SFA are themselves less toxic than DNL SFA due to unique partitioning within the liver. These experiments will utilize the methionine-choline-deficient model of murine fatty liver disease, in which liver injury is known to depend upon the hepatic accumulation of DNL SFA. Dietary and DNL fatty acids will be individually traced through several metabolic pathways in vivo by labeling with unique stable isotopes.
Specific Aim 2 will explore the cellular events by which DNL leads to hepatocyte death. Experiments will confirm that hepatocyte death is directly linked to DNL using pharmacologic and genetic means to induce DNL, and will target various intracellular signaling pathways activated by DNL to determine which ones mediate cell death.
Specific Aim 3 will test the hypothesis that DNL SFA are pivotal mediators of fatty liver disease not only in the MCD-fed mouse, but also in a standard, non-MCD model of diet-induced obesity. As in the MCD model, dietary SFA are expected to play a limited role in the pathogenesis of diet-induced liver injury in comparison to DNL SFA. The ultimate goal of the project is to demonstrate the importance of DNL to fatty liver disease and by analogy, the importance of dietary sugar and other nutrients that stimulate DNL. The information gained from this research will guide policymakers to develop nutritional guidelines that minimize excess DNL.

Public Health Relevance

There is a strong belief that the modern American diet, which is enriched in both sugar and saturated fat, is responsible for many health problems including fatty liver disease. This research proposal is based on the hypothesis that sugar, rather than saturated fat, is the dietary nutrient with the greatest toxicity toward the liver. Interestingly, when sugar is eaten together with saturated fat, the combination is extraordinarily toxic to the liver. We believe this enhanced toxicity is not attributable to an additive effect of the two nutrients, but rather to the ability of saturated fat to enhance the toxicity of sugar. The goal of this project is to emphasize the pivotal role of dietary sugar as a mediator of fatty liver disease. We hope to use the information gained from the research to influence policymakers to take steps to reduce sugar consumption in the U.S.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK068450-09
Application #
8639544
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Doo, Edward
Project Start
2004-08-01
Project End
2015-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
9
Fiscal Year
2014
Total Cost
$394,639
Indirect Cost
$104,460
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Duwaerts, Caroline C; Maher, Jacquelyn J (2014) Mechanisms of Liver Injury in Non-Alcoholic Steatohepatitis. Curr Hepatol Rep 13:119-129
Kamalakar, Archana; Bendre, Manali S; Washam, Charity L et al. (2014) Circulating interleukin-8 levels explain breast cancer osteolysis in mice and humans. Bone 61:176-85
Maher, Jacquelyn J (2013) Retinol binding protein 4 and fatty liver: A direct link? Hepatology 58:477-9
Maher, Jacquelyn J (2011) New insights from rodent models of fatty liver disease. Antioxid Redox Signal 15:535-50
Niemann, Claus U; Xu, Fengyun; Choi, Soojinna et al. (2010) Short passive cooling protects rats during hepatectomy by inducing heat shock proteins and limiting the induction of pro-inflammatory cytokines. J Surg Res 158:43-52
Pickens, Michael K; Ogata, Hisanobu; Soon, Russell K et al. (2010) Dietary fructose exacerbates hepatocellular injury when incorporated into a methionine-choline-deficient diet. Liver Int 30:1229-39
Maher, Jacquelyn J (2010) Trunk fat as a determinant of liver disease. Gastroenterology 138:1244-6
Soon Jr, Russell K; Yan, Jim S; Grenert, James P et al. (2010) Stress signaling in the methionine-choline-deficient model of murine fatty liver disease. Gastroenterology 139:1730-9, 1739.e1
Pickens, Michael K; Yan, Jim S; Ng, Raymond K et al. (2009) Dietary sucrose is essential to the development of liver injury in the methionine-choline-deficient model of steatohepatitis. J Lipid Res 50:2072-82
Maher, Jacquelyn J (2009) DAMPs ramp up drug toxicity. J Clin Invest 119:246-9

Showing the most recent 10 out of 15 publications